Skip to main content

Awaken Hair Loss Study

Awaken hair loss study

A clinical study for men with Androgenetic Alopecia.

Evaluating changes in hair count and scalp coverage with an investigational topical treatment.

Study at a glance

  • Male participants
  • Men 18–55
  • Investigational topical treatment or placebo
  • Once-daily application
  • Up to 60 weeks

What participation may involve

  • Screening to determine eligibility
  • Documenting daily dose application in an electronic dosing diary
  • Daily use of investigational topical treatment or placebo as directed
  • Ongoing follow-up throughout participation

There are other requirements for taking part in the Awaken Hair Loss Study. For more information contact the Research Department at

346-250-1771 | research@dermlasersurgery.com

Inclusion Criteria

You may participate if you are/have:

  • Moderate to advanced male pattern hair loss
  • Thinning hair at the crown
  • Study staff will review additional criteria to determine eligibility

*Additional inclusion / exclusion criteria will be discussed during pre-screening or screening visits

Exclusion Criteria

More details TBA

For more information contact the Research Department at

346-250-1771 | research@dermlasersurgery.com

UltraClear Study

ultraclear clinical trials

If you are 35-70 years of age and are bothered by laxity and sagging skin in the lower face and neck, you may be eligible to participate in a laser research study using an FDA-cleared device designed to address signs of aging, lines, wrinkles, and lax skin.

Study Requirements

  • Will last approximately 9 months
  • Two ablative resurfacing laser treatments will be performed with a focus on the lower face and full neck
  • A total of 7 visits will be scheduled
  • Clinical photographs will be taken at each visit
  • Study treatments, post-procedure care products, and follow-up provided at no cost
  • No compensation is provided for participation
  • Additional pre and post procedure guidelines will be discussed at screening

There are other requirements for taking part in the Laxity & Lifting Study. For more information contact the Research Department at

346-250-1771 or research@dermlasersurgery.com

Inclusion Criteria

You may participate if you are/have:

  • Men & Women, Ages 35-65
  • Fitzpatrick Skin Type I-IV
  • Must be rated as Moderate to Very Severe Sagging of lower face and neck

*Additional inclusion / exclusion criteria will be discussed during pre-screening or screening visits

Exclusion Criteria

You may not participate if one of the following applies to you:

  • Must not have a compromised ability for wound healing
  • Must not have had injectable soft tissue fillers within the last 12 months
  • Must not have had neurotoxins within the last 4-months in the treatment area
  • Must not have had another energy-based device treatment in the last 3-6 months

*Additional inclusion / exclusion criteria will be discussed during pre-screening or screening visits

Sofwave31 Clinical Trial

sofwave31-study-poster

Seeking adults age 40 to 55 with facial wrinkles and laxity in the lower face, submental, and upper neck. This study lasts 20-34 weeks and includes 1 or 2 Sofwave treatments spaced 4-6 weeks apart, as well as 3 follow-up visits at 4 weeks, 12 weeks, and 24 weeks for clinical photographs, surveys, and assessments.

There are other requirements for taking part in the Sofwave31 Study. For more information contact the Research Department at

346-250-1771 or research@dermlasersurgery.com

Inclusion Criteria

You may participate if you are/have:

  • Healthy female and male subjects between the ages 40-55.
  • Non-Smoker.
  • Fitzpatrick skin type I-VI.
  • Desire to lift facial lax skin, neck and/or submental and/or improve facial wrinkles appearance.
  • Presence of mild to moderate multi-motor laxity in the lower face and submental area.
  • Able and willing to comply with all visits, study treatments and evaluation schedules and requirements.
  • Able to understand and provide written Informed Consent.
  • If you are a woman within the child-bearing age- you are using a reliable method of birth control at least 3 months prior to study enrollment.
  • Agree not to undergo any other facial cosmetic treatment for a period of 3 months following last SofWave study treatment.
  • Stable weight over the last 12 weeks and throughout the duration of the study.
  • Agree to adhere to safe sun practices and daily use of broad-spectrum sunscreen SPF 30+.
  • If you are male with facial hair in the study treatment area – you are willing to trim or shave as needed to allow consistent standardized photography.

Exclusion Criteria

You may not participate if you are/ have:

  • Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
  • Presence of any active systemic or local infections.
  • Open wounds or lesions within the study treatment area.
  • Presence of active local skin disease that may alter wound healing.
  • Tattoo or former tattoo at or near study treatment area.
  • Uncontrolled diabetes mellitus.
  • Skin cancer in the area to be treated with the study device. History of any other non-melanoma skin cancers in the past 5 years within the study treatment area (head and neck).
  • Severe solar elastosis (skin damage).
  • History of smoking in the past 10 years.
  • History of chronic drug or alcohol abuse.
  • Excessive subcutaneous (beneath the skin) fat on the cheeks.
  • Significant scarring in the area to be treated with the study device, or history of keloids(raised overgrowth of scar tissue).
  • Severe or cystic facial acne, and/or Accutane use during the past 6 months.
  • Pacemakers and electronic device implants in the study treatment area.
  • Presence of a metal stent or implant in the facial area (dental implants and/or braces are not excluded).
  • Inability to understand the study plan or to provide a signed informed consent.
  • History of cosmetic treatments in the facial area to be treated with the study device, including:
  • Chemical peels, microneedling, dermabrasion, energy-based devices, or laser treatments in the past 6 months.
  • Injectable filler treatments in the past 6 months.
  • Injectable neuromodulator treatment in the past 4 months.
  • Cosmetic surgical procedures in the study treatment area, including but not limited to facelift in the past 12 months.
  • Taking anti-platelet or anti-coagulant within the past 2 weeks.
  • Taking psychiatric medications within the past 2 weeks.
  • As per the study doctor’s discretion, any physical or mental condition which might make it unsafe for you to participate in this study.

Past clinical trials below:

Fraxel FTX/FD Study – CLOSED

Seeking adults aged 50 to 70 for a study comparing two laser devices (Fraxel Dual and Fraxel FTX) for the potential treatment of photodamaged skin. Participants will undergo a single split-face laser treatment, with one side of the face treated using Fraxel Dual and the other with Fraxel FTX. The study includes approximately 5 clinic visits over a 4-month period. All participants will return for follow-up visits at 24 hours and 3 days post-treatment. Additional follow-up visits will vary by participant group.

 

Thermage FLX Study – CLOSED

Seeking adults aged 30 to 60 for a study evaluating the Thermage FLX treatment for the potential treatment of fine lines, wrinkles, and lax skin of the neck, abdomen, upper arms, and face. All participants will be receiving a single Thermage FLX treatment. The study includes approximately 4 clinic visits over a 6-month period, including a screening visit, a baseline visit, a third visit after 90 days, and a final visit after 180 days. Clinical photographs, surveys, and assessments will be completed at each visit, and participants will receive pre- and post-treatment care instructions after every study treatment.

 

LAURITE 1 Study – CLOSED

The LAURITE 1 Study will assess the effectiveness and safety of an investigational drug called IPN10200 to see if it helps improve the appearance of medium to heavy frown lines in adults and whether it provides a long-lasting effect. IPN10200 is based on botulinum toxins that doctors can give to people to temporarily relax facial muscles and smooth lines and wrinkles.

Participation in the LAURITE 1 Study lasts approximately 1 year. After a screening period of up to 20 days to see if you are medically eligible to take part, you will be randomly selected (like flipping a coin) to receive a single treatment of either the investigational drug or placebo, which looks like the investigational drug but contains no active ingredients. Participants have a 3 out of 4 chance of receiving the investigational drug.The investigational drug or placebo will be injected into in the area between the eyebrows.

 

Fraxel FTX Study – CLOSED

Seeking adults age 21 to 60 with visible photodamage, fine lines, or uneven pigmentation in the face.

 

Perioral Lines & Wrinkles Study – CLOSED

If you are between 40-80 years old and are bothered by advanced signs of skin, you may be eligible to participate in a laser research study using an FDA-cleared device designed to address signs of skin aging, lines and wrinkles around the mouth.

 

Ultraclear clinical trial – CLOSED

Women and men 60+ years old with skin types 1-4 and perioral and cheek wrinkles.

Patients will be treated with Ultraclear, an FDA cleared laser using fractionated technology to help reverse signs of aging, including wrinkles, sun spots, scars and pigmentation.

Patients will be treated by a board certified dermatologist and will receive 3 Ultraclear treatments 6-8 weeks apart. Follow up visits will take place 1 and 3 months after the third treatment.

 

Sofwave Clinical Trial – CLOSED

Clinical trial of a newly FDA cleared device using ultrasound technology. This device treats facial lines & wrinkles and lifts the brow and skin on the neck & submental region.

Participants Must:

  • Be between the ages of 35-70
  • Non -Smoker
  • Desire to improve facial lines and wrinkles
  • Has NOT had a facial skin-tightening procedure in the past year, including injectable fillers of any type
  • Has NOT had Botox or other neuromodulators within the past 6 months
  • Has NOT had any lasers rejuvenation treatments within the past 6 months

 

Rosacea Study – CLOSED

Dr. Paul Friedman of Dermatology & Laser Surgery Center in Houston, TX is conducting a clinical trial, using the Vbeam Prima laser, to improve facial flushing, redness, and the appearance of visible blood vessels, when used in combination with a topical prescription cream (RHOFADE™ (oxymetazoline HCl) Cream, 1%) for erythematotelangiectatic rosacea.

The study treatment by the laser device heats the tiny, broken blood vessels on the face and should improve flushing and redness. The study will try to determine if the areas treated with the laser and the topical prescription cream will have improved outcomes, compared to what would have been obtained with the topical prescription cream alone. The VBEAM PRIMA device used in this study was recently cleared by the Food and Drug Administration (FDA). The topical prescription cream used in the study, Allergen’s RHOFADE™ (Oxymetazoline Hydrochloride) 1% Cream is FDA-cleared for the topical treatment of persistent facial erythema associated with rosacea in adults.

The treatment is a series of three treatments, each of which take about 15 minutes. Treatments are performed in the office. The trial is free and includes reimbursement of $75 for each tube of RHOFADE not covered by insurance.

Study candidates must meet the following criteria:

  • Are a healthy male or female of 18 to 75 years of age
  • Have erythematotelangiectatic rosacea with clinician erythema assessment (CEA) and subject self-assessment (SSA) of “moderate” or “severe”
  • Are not undergoing any form of treatment for active cancer or do not have a history of skin cancer or any other cancer on the face
  • Not pregnant or planning to become pregnant during the study duration

 

Melasma Study: laser combined with the tranexamic acid pill – CLOSED

Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 50 with moderate melasma or severe melasma. Participants will receive up to 5 monthly laser treatments to half the face and need to take a pill twice a day for 4 months. Follow up visits are required 1 month, 3 months and 6 months after the final treatment.  Compensation of up to $150 will be provided based on completed visits.

Inclusion Criteria:

  • Healthy male and female subjects between the ages 18 to 50
  • Fitzpatrick skin types I through VI (all skin types)
  • Moderate or severe melasma
  • Willing to participate in study photography
  • Able and willing to comply with all visit, treatment, and evaluation schedules
  • Able to understand and provide written informed consent

Exclusion Criteria:

  • Pregnant, nursing women, current use of hormonal birth control medication or any hormonal therapy, or history of >2 spontaneous abortions
  • Use of topical steroids on the face within 1 month of study enrollment, use of topical hydroquinone on the face within 3 months of study enrollment, laser or dermabrasion to the face within 6 months of study enrollment
  • Regular use of tanning parlors, or occupation involving primarily outdoor activities
  • Current treatment with blood thinning medications
  • History of thrombosis, thrombophilia, or thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and/or cerebral thrombosis, family history of thromboembolic disease
  • History of seizures or known light sensitive seizure disorder, stroke, or subarachnoid hemorrhage
  • History of kidney dysfunction
  • History of cancer, or active smoking
  • Significant cardiovascular or respiratory disease (end-stage congestive heart failure or chronic obstructive pulmonary disease)
  • History of acquired disturbances of color vision
  • Known allergy to tranexamic acid
  • As per the investigator’s discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

For More Information Contact The Research Department At
713-900-3900 or info@dermlasersurgery.com